Sarcoma, wanda ke faruwa a cikin samari kuma mummunan kumburi ne wanda aka samo daga ƙwayoyin cuta (ciki har da nama da tsoka). Sarcomas suna da haɗari sosai kuma suna haɓaka cikin sauri! Sarcomas na yau da kullun sun haɗa da osteosarcoma, leiomyosarcoma, lymphosarcoma, da sarcoma synovial. Leiomyoma, lymphosarcoma, da sarcoma na synovial na iya haɓaka haɓakar jini a farkon matakin.
Hanyar da aka fi so na sarcoma shine tiyata. Domin neman magani na tsatsauran ra'ayi, likitocin gida yawanci suna buƙatar marasa lafiya a yanke musu gaɓoɓinsu. Duk da haka, a halin yanzu yana da wuya a yi maganin liposarcoma mara kyau ko ci gaba da leiomyosarcoma da ke faruwa a bayan peritoneum kuma suna da manyan ciwace-ciwace. Asibitoci a gida da waje suna riƙe yawancin gaɓoɓi sannan su yi aikin rediyo.
Sarcoma baya kula da magungunan chemotherapy! Har ila yau, ingancin aikin rediyo na gida ba shi da kyau, amma da zarar ƙwayoyin huhu ba su da tasiri.
Palbociclib capsule babban zaɓi ne mai hanawa na kinases masu dogaro da cyclin CDK4 da CDK6. Shi ne kuma ciwon nono na farko immunotherapy inhibitor to be approved by the US FDA. Palbociclib capsules are targeted drugs for the treatment of sarcoma.
Ta yaya Palbociclib ke aiki: Duk ƙwayoyin rai suna fuskantar rabe-raben ƙwayoyin halitta, kuma Palbociclib na iya dakatar da tsarin rarraba kwayar halitta, da kuma haɗa Palbociclib tare da wasu hanyoyin magance cututtukan kansa kamar maganin endocrine, chemotherapy, da sauran hanyoyin kwantar da hankali da aka yi niyya na iya magance nau'o'in kansar da yawa sakamakon warkarwa.
Neman da aka yi niyya na iya amfani da magunguna iri-iri da sauran tsoma baki don ganowa da kuma farma ƙwayoyin kansa ba tare da cutar da ƙwayoyin halitta ba. Dokta Peter J. O'Dwyer ya ce ban da neutrophils, Palbociclib yana da tasirin kwayar halitta kuma karami ne, kuma maganin na iya hana ci gaban ciwan ciwace ciwace a cikin ƙari. Yayin da muke gano sabbin ayyuka na CDK4 / 6 na manufa, zamu iya haɓaka sabbin haɗuwa da ƙwayoyi azaman masu ba da kariya ga cutar kansa.
Dangane da sakamakon binciken da sakamakon gwaji na farko na asibiti da masana kimiyya a Jami'ar Pennsylvania suka buga a cikin mujallar JAMA Oncology, sakamakon gwajin gwaji na kashi 2 na marasa lafiya na sarcoma 29 ya nuna cewa Palbociclib na iya samun matsakaicin ci gaba ba tare da 66 ba. % na marasa lafiya makonni 12. Palbociclib yana da tasiri a cikin maganin sarcoma kuma yana iya tsawaita rayuwar marasa lafiya marasa ci gaba.
